Vibrating shoe improves walking stability
- Trial ID
- NCT06975059
- Official Title
- Using the NUSHU Shoe to Analyze Gait Balance and Vibrotactile Feedback in Early, Moderate and Advanced PD Patients and Healthy Controls
- Goal
- Vibrating shoe improves walking stability
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Weill Medical College of Cornell University
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- Parkinson's Disease (PD)
- Interventions
- NUSHU shoe
Plain-Language Summary
The goal is to map how gait and balance change across early, moderate, and advanced Parkinson's, and to test whether vibrotactile foot cues from the NUSHU shoe can improve stability and step timing. The approach uses a sensor-packed, wearable shoe that records steps, sway, and asymmetry while delivering timed vibrations to the foot to provide rhythmic cues that may help with balance and gait, it is noninvasive and designed to be used alongside usual medications like levodopa rather than replace them. Eligible participants are adults 18 and older with a PD diagnosis who can walk independently and score 22 or higher on the MoCA, and the study also enrolls healthy adults 18 and older with no neurological disease; people who cannot wear the device or have other major brain or gait disorders are excluded.
Locations
- Weill Cornell, New York, New York, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying NUSHU shoe. The goal is to map how gait and balance change across early, moderate, and advanced Parkinson's, and to test whether vibrotactile foot cues from the NUSHU shoe can improve stability and step timing. The approach uses a sensor-packed, wearable shoe that records steps, sway, and asymmetry while delivering timed vibrations to the foot to provide rhythmic cues that may help with balance and gait, it is noninvasive and designed to be used alongside usual medications like levodopa rather than replace them. Eligible participants are adults 18 and older with a PD diagnosis who can walk independently and score 22 or higher on the MoCA, and the study also enrolls healthy adults 18 and older with no neurological disease; people who cannot wear the device or have other major brain or gait disorders are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.